Twenty-two newbie managers, fresh from B-schools across India, are raring to go. Only, they won’t make spreadsheets to sell soaps or fizzy drinks. From June, they will assist senior bureaucrats across 11 districts of Jharkhand where the Centre is funding uplift schemes. These managers — from IIT-Kharagpur, Tata Institute of Social Sciences (TISS)-Mumbai, Visva-Bharti in Bengal’s Santiniketan, XISS-Ranchi, XLRI-Jamshedpur and others — are Prime Minister’s Rural Development Fellows in some of...

-The Telegraph The decade-long flow of funds from the Bill and Melinda Gates Foundation into India’s HIV control efforts will stop from June 2013, a foundation official said today, intensifying fears among sections of health activists about the future of the programme. Avahan was the first large-scale health initiative in India to be supported by the foundation, said to be t he world’s largest philanthropic organisation, and will be the first to...

-PTI German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week. Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company’s decision to cut the price of the life-extending kidney and liver cancer drug “is a clear...

-The United Nations Secretary-General Ban Ki-moon today called on India to lead the way in improving health services for women and children, stressing that addressing this issue is a crucial investment in the future of the South Asian nation. "Around the world, some eight million women and children die from preventable causes each year. Almost two million of them are Indian," Mr. Ban said in his remarks at a reception in support...

India is coming under increasing pressure from the U.S. and the European Union for the strict patentability criteria it applies for medicines. AS was only to be expected, the two landmark decisions made by the Indian patent office in recent times concerning pharmaceutical patent cases have not gone down well with the multinational drug industry. First, there was the rejection in 2006 of the patent application by the Swiss multinational...